Results 191 to 200 of about 12,867 (321)

Transient Reverse Takotsubo Cardiomyopathy Following a Spider Bite in Greece

open access: gold, 2015
Lykourgos Christos Alexakis   +4 more
openalex   +1 more source

Narrating Entanglement Without Dehumanisation in Contemporary Eco‐Fiction

open access: yesFuture Humanities, Volume 4, Issue 1, May 2026.
ABSTRACT This essay presents a comparative analysis of two contemporary works of eco‐fiction, Richard Powers's The Overstory (2018) and Eleanor Catton's Birnam Wood (2023). Both novels use multiperspective narration in the service of entanglement narratives, forms of storytelling that emphasise the interconnection of human and nonhuman life.
Diana Rose Newby
wiley   +1 more source

Understanding Pollination in Urban Food Production: The Importance of Data Validation and Participant Feedback for Citizen Science Project Design

open access: yesPLANTS, PEOPLE, PLANET, Volume 8, Issue 1, Page 157-175, January 2026.
Urban agriculture depends on insect pollination, but knowledge gaps persist due to difficulties accessing diverse growing spaces. We developed a citizen science approach for monitoring insect visits to crops and compared grower‐collected data to that of a trained researcher while also gathering participant feedback.
Elizabeth Nicholls   +7 more
wiley   +1 more source

Comparative venomics suggests an evolutionary adaption of spider venom from predation to defense. [PDF]

open access: yesCommun Biol
Lüddecke T   +8 more
europepmc   +1 more source

CELLULITIS FROM SPIDER BITE & ITS HOMOEOPATHIC APPROACH

open access: bronze, 2020
Sunil Prasad   +4 more
openalex   +1 more source

A Phase II Pilot Study of Anti‐PD‐L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation

open access: yesCancer Medicine, Volume 14, Issue 23, December 2025.
ABSTRACT Background Immunostimulatory effects of PARP inhibitors could increase sensitivity to immune checkpoint inhibitors. The previous Phase II trial (MEDIOLA) reported clinical benefits of durvalumab and olaparib (D + O) in patients with germline BRCA‐mutated (gBRCAm) HER2‐negative metastatic breast cancer.
Takeo Fujii   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy